This simple change could promote the development of IgM into the frontline and allow the biomedical industry to fully utilize IgM’s advantages in preventing and/or treating illnesses beyond infectious diseases, such as cancer and autoimmune disorders. This evidence concerns the gene CD40LG and infectious disease.